Minerva Neurosciences (NERV) Rating Lowered to Hold at Zacks Investment Research

Minerva Neurosciences (NASDAQ:NERV) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company’s pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson’s disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences, Inc. is based in Cambridge, MA, United States. “

Other equities analysts have also recently issued reports about the company. ValuEngine cut Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. BidaskClub upgraded Minerva Neurosciences from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. Minerva Neurosciences presently has a consensus rating of “Hold” and an average target price of $12.75.



Shares of Minerva Neurosciences stock opened at $6.50 on Tuesday. Minerva Neurosciences has a 12 month low of $6.55 and a 12 month high of $6.80.

Minerva Neurosciences (NASDAQ:NERV) last announced its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). research analysts anticipate that Minerva Neurosciences will post -1.46 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Alps Advisors Inc. boosted its stake in shares of Minerva Neurosciences by 21.0% in the 1st quarter. Alps Advisors Inc. now owns 51,906 shares of the biopharmaceutical company’s stock valued at $324,000 after buying an additional 9,021 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Minerva Neurosciences by 47.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 40,835 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 13,199 shares during the period. Schwab Charles Investment Management Inc. boosted its stake in shares of Minerva Neurosciences by 64.7% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 57,000 shares of the biopharmaceutical company’s stock valued at $434,000 after buying an additional 22,400 shares during the period. Ascend Capital LLC boosted its stake in shares of Minerva Neurosciences by 4.8% in the 4th quarter. Ascend Capital LLC now owns 819,347 shares of the biopharmaceutical company’s stock valued at $4,957,000 after buying an additional 37,659 shares during the period. Finally, Franklin Resources Inc. boosted its stake in shares of Minerva Neurosciences by 3.6% in the 4th quarter. Franklin Resources Inc. now owns 1,235,000 shares of the biopharmaceutical company’s stock valued at $7,472,000 after buying an additional 42,700 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Get a free copy of the Zacks research report on Minerva Neurosciences (NERV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply